Merit Medical Shares Await Key Catalysts for Momentum Shift

Shares of Merit Medical Systems are trading quietly around $93.24 as investors monitor two significant near-term developments. Market attention remains fixed on the company’s upcoming third-quarter results, expected around October 29, and the anticipated December decision regarding transitional pass-through reimbursement approval for the WRAPSODY product.

Financial experts covering Merit Medical maintain an optimistic stance, with nine analysts collectively rating the stock as a “Moderate Buy.” Their average price target of $107.00 suggests potential upside of approximately 14.3% from current trading levels. This bullish perspective reflects confidence in the company’s long-term growth trajectory and positive revenue and earnings projections.

The company’s recent performance supports this optimism. Second-quarter results demonstrated strong operational execution, with GAAP revenue climbing 13.2% to $382.5 million. Non-GAAP earnings per... Read more...